Prelude Therapeutics (PRLD) Current Deferred Revenue (2024 - 2026)
Prelude Therapeutics' (PRLD) quarterly Current Deferred Revenue came in at $31.0 million in Q1 2026, down 8.25% quarter-over-quarter from $33.7 million in Q4 2025.
Prelude Therapeutics (PRLD) Current Deferred Revenue (2024 - 2026) Analysis & Trends
Prelude Therapeutics has disclosed Current Deferred Revenue across 3 years of filings, most recently posting $31.0 million for Q1 2026.
- Current Deferred Revenue for Q1 2026 came in at $31.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $31.0 million (changed N/A YoY), and the FY2025 annual result was $33.7 million, changed N/A from the prior year.
- Current Deferred Revenue came in at $31.0 million for Q1 2026 at Prelude Therapeutics, down from $33.7 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $33.7 million in Q4 2025 to a low of $3.0 million in Q2 2024.
- The 3-year median for Current Deferred Revenue is $31.0 million (2026), against an average of $22.6 million.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | Prelude Therapeutics | 314.40 Mn | 169.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.95 Mn |
| Dec 31, 2025 | 33.73 Mn |
| Jun 30, 2024 | 3.00 Mn |